## VPA10774/054/003

## Selehold 120 mg spot-on solution for dogs 10.1–20.0 kg

| Variation        | Summary   | Date     |
|------------------|---|----------|
| Vet - G.I.18     | VRA-S - Vet - G.I.18 - One-off alignment of the product<br>information with version 9.0 (or the latest version of the QRD<br>templates that are in effect at the time that this one-off variation is<br>submitted) of the QRD templates i.e. major update of the QRD<br>templates in accordance with Regulation (EU) 2019/6, for<br>veterinary medicinal products placed on the market in accordance<br>with Directive 2001/82/EC or Regulation (EC) No 726/2004 -<br>G.I.18 Safety, Efficacy, Pharmacovigilance changes - One-off<br>alignment of the product information with version 9.0 (or the<br>latest version of the QRD templates that are in effect at the time<br>that this one-off variation is submitted) of the QRD templates i.e.<br>major update of the QRD templates in accordance with<br>Regulation (EU) 2019/6, for veterinary medicinal products placed<br>on the market in accordance with Directive 2001/82/EC or<br>Regulation (EC) No 726/2004 | 15/09/23 |
| Vet - B12 c)     | VNRA - Vet - B12 c) - c) Minor changes to an approved test<br>procedure for an in-process test - B12 c) Changes to the quality<br>part of the dossier: Minor changes — to an approved test<br>procedure for an in-process test — for active substance; — for the<br>finished product  | 24/03/23 |
| Vet - B47 d)     | VNRA - Vet - B47 d) - d) To reflect compliance with the Ph. Eur.<br>by removing reference to the internal test method and test method<br>number - B47d) Changes to the quality part of the dossier:<br>Change to comply with Ph. Eur. or with a national pharmacopoeia<br>of a Member State: — to reflect compliance with the Ph. Eur. by<br>removing reference to the internal test method and test method<br>number   | 02/03/23 |
| Vet - B4 a)      | VNRA - Vet - B4 a) - a) Change in the manufacturer of the active<br>substance (including relevant quality control testing sites) - B4 a)<br>Changes to the quality part of the dossier: Changes to the<br>production process or the storage of active substance where no<br>Ph. Eur. CEP is part of the approved dossier of an active<br>substance (including starting material, reagent or intermediate) -<br>change in the manufacturer of the active substance (including<br>relevant quality control testing sites)   | 02/03/23 |
| Vet - F.I.d.1 c) | VRA-R - Vet - F.I.d.1 c) - c) Extension or introduction of a re-test<br>period/storage period supported by real time data - F.I.d.1 c)<br>Quality Changes - Active Substance - Stability -Change in the<br>re-test period/storage period of the active substance where no Ph.<br>Eur. Certificate of Suitability covering the retest period is part of<br>the approved dossier - Extension or introduction of a re-test<br>period/storage period supported by real time data  | 08/08/22 |
| B.II.b.5.z       | IA - B.II.b.5.z - z Other variation - B.II.b.5.z - QUALITY<br>CHANGES - FINISHED PRODUCT - Manufacture - Change to  | 28/02/22 |

|            | in-process tests or limits applied during the manufacture of the finished product - Other variation   |          |
|------------|---|----------|
| B.II.d.2.a | IA - B.II.d.2.a - a) Minor changes to an approved test procedure -<br>B.II.d.2.a - QUALITY CHANGES - FINISHED PRODUCT -<br>Control of finished product - Change in test procedure for the<br>finished product - Minor changes to an approved test procedure | 28/02/22 |